

What is Aducanumab?

Jarrel Clark, MPH

Data Collector, Maya Angelou Center for Health Equity





Aducanumab is an amyloid beta directed antibody indicated to treat Alzheimer's Disease.



Beta amyloid is a protein fragment snipped from an amyloid precursor protein (APP) located in the brain.

Approved

Aducanumab has been approved under the accelerated approved pathway instituted by the Food and Drug Administration as of June 2021.

This new medication may have an effect on the progression of cognitive change and is the newest medication for Alzheimer's Disease in over 15 years.



Eligible Patients



A physician must confirm the presence of amyloid beta plaques in the brain before providing this treatment.

According to the Alzheimer's Association, treatment with Aducanumab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease.

How is Given? What is the Cost?

The drug is administered through IV via a 45-60 minute infusion once every four weeks.

Aducanamab is about \$4,312 per infusion with an annual cost being around \$51,000 a year.



Side Effects

- Some common side effects include amyloid-related imaging abnormalities (ARIA), headache, and fall.
- A potentially serious side effect is an allergic reaction to the drug.




Access



- This is a new medication that was recently approved by the FDA so distribution may take some time.
- Please speak with your doctor to see if the medication is available and right for you.

Infographic



References

Center for Drug Evaluation and Research. (n.d.).
Aducanumab (marketed as Aduhelm)
Information. U.S. Food and Drug
Administration.
<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aducanumab-marketed-aduhelm-information>.

Aducanumab Approved for Treatment of
Alzheimer's Disease. Alzheimer's Disease
and Dementia. (n.d.).
<https://www.alz.org/alzheimers-dementia/treatments/aducanumab>.
Aducanumab Approved for Treatment of
Alzheimer's Disease. Alzheimer's Disease
and Dementia. (n.d.).
<https://www.alz.org/alzheimers-dementia/treatments/aducanumab>.

Selkoe DJ. Alzheimer disease and
aducanumab: adjusting our
approach. Nat Rev Neurol. 2019
Jul;15(7):365-366. doi:
10.1038/s41582-019-0205-1. PMID:
31138932.

Continued

Schneider L. A resurrection of aducanumab for Alzheimer's disease. *Lancet Neurol.* 2020 Feb;19(2):111-112. doi: 10.1016/S1474-4422(19)30480-6. Epub 2019 Dec 4. PMID: 31978357.

U.S. National Library of Medicine. (2020, August 18).
APP gene: MedlinePlus Genetics. MedlinePlus.
<https://medlineplus.gov/genetics/gene/app/>.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A β plaques in Alzheimer's disease. *Nature.* 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Update in: *Nature.* 2017 Jun 21;546(7659):564. PMID: 27582220.